Study identification

EU PAS number

EUPAS1000000438

Study ID

1000000438

Official title and acronym

Cross-Sectional Survey of Rheumatologists and Dermatologists to Assess the Effectiveness of the Baricitinib Additional Risk Minimization Measures in Canada

DARWIN EU® study

No

Study countries

Canada

Study description

Survey study of HCPs to assess effectiveness of aRMM.

Study status

Planned
Research institutions and networks

Institutions

YOLARX Consultants
France
First published:
06/03/2024
Institution Non-Pharmaceutical company ENCePP partner

Contact details

Philippe Assad

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only